Abstract

The prostate cancer vaccine has significant influences on males, and the cancer among American men has second highest prevalence among all cancers. Both the prevalence and mortality rates of prostate cancer in America are increasing each year. Researchers have been working to improve and innovate the way prostate cancer is diagnosed and treated. One promising direction is immunotherapy. Scientists have been working on a vaccine for prostate cancer for decades, and FDA only passes Sipuleucel-T as prostate cancer vaccine, but many other prostate cancer vaccines have been developed. Therefore, after synthesizing many papers, this paper explains the principles, latest progress, the advantages and disadvantages of all the vaccines developed so far, and proposes that future researchers should improve the prostate cancer vaccine in the direction of combination therapy, and conduct in-depth research to explore the prostate cancer vaccines that are currently showing an excellent trend, and to optimize the Sipuleucel-T.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call